|
|
Vaccine Detail
|
Recombinant Adenovirus-hIFN-beta Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Adenovirus-hIFN-beta Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007124
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IFNB1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Park et al., 2010)
- Detailed Gene Information: Click Here.
- Preparation: The therapy combines conditionally replicating adenovirus (CRAd) and replication-defective adenovirus expressing interferon-beta (Park et al., 2010).
- Description: AThis is for Mesothelioma Cancer (NCT00066404). recombinant replication-defective adenovirus which encodes the gene for the cytokine human interferon-beta (IFN-beta). Once inserted into and replicating in host tumor cells, recombinant adenovirus-hIFN-beta expresses human IFN-beta, which may stimulate an antiproliferative natural killer (NK) cell response against tumor cells and induce caspase-mediated tumor cell apoptosis. (NCI04) (NCIT_C28550).
|
| Host Response |
|
|
| References |
NCIT_C28550: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28550]
NCT00066404: [https://clinicaltrials.gov/ct2/show/NCT00066404?term=Recombinant+Adenovirus-hIFN-beta&rank=1]
Park et al., 2010: Park MY, Kim DR, Jung HW, Yoon HI, Lee JH, Lee CT. Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta. Cancer gene therapy. 2010; 17(5); 356-364. [PubMed: 19893592].
|
|
